13972139 · Active · incorporated 4 years, 6 months ago · Cambridge
Biotech Biotech & Life Sciences Drug Discovery Series A
IsomAb is a biotechnology company developing isoform-specific antibodies for treating life-limiting diseases, including a therapeutic antibody for coronary artery disease.
Isomab is a private limited company registered at Companies House under number 13972139, incorporated on 11 March 2022, with a registered office in Cambridge. Its current status on the register is active. Its filed nature of business is research and experimental development on biotechnology (SIC 72110). Sonde has indexed 58 filings for this company, including 2 funding rounds. Its most recent round closed in January 2025, raising £7.5m.
| Round | Closed | Raised | Price per share |
|---|---|---|---|
| Round 2 | Jan 2025 | £7.5m | £1.00 |
| Round 1 | Dec 2022 | £805k | £22.58 |
Showing the 10 most recent of 58 filings.
See the complete cap table with every shareholder, founder tags, dilution across 26 share allotments, round-by-round fundraising history, and the full filing timeline — parsed from official Companies House documents.
Create a free account Sign inFree accounts open 3 companies in full detail — no card required.